Pricing Log in Create free account
Friday 6 November 2026 Export EW’s income statement to Excel — free account

Edwards Lifesciences Corporation

EW Healthcare Medical Devices

Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024.

Revenue
+10.5%
EPS
+6.00%
Free cash flow
−1.84%
Total debt
+0.10%

Quarter to September 2026, against a year earlier

101.64 0.82 +0.81%
Market cap
$58.1B
P/E
56.7×
Fwd P/E
36.5×
Dividend yield
—
F-score
5/9
Altman Z
11.54
Beneish M
−2.48
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Edwards Lifesciences Corporation (EW) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 7 added · 31 modified
P2I1A: no comparison — incorporated by reference
8-K Nov 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Aug 25, 2026 5.02 Departure or appointment of directors or officers Officer departure
10-Q Jun 30, 2026 P1I2: 8 added · 27 modified
P2I1A: no comparison — incorporated by reference
8-K Jul 23, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 7, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026 P1I2: 6 added · 7 removed · 33 modified
P2I1A: no comparison — incorporated by reference
8-K May 2, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure
8-K Apr 23, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 9 added · 2 removed · 38 modified
1A: 18 added · 8 removed · 40 modified
7: 15 added · 36 removed · 42 modified
8-K Feb 10, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 9, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025 P1I2: 3 added · 22 modified
P2I1A: no comparison — incorporated by reference
8-K Oct 30, 2025 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Oct 30, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025 P1I2: 5 added · 4 removed · 20 modified
P2I1A: no comparison — incorporated by reference
8-K Jul 24, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025 P1I2: no comparison — the earlier filing's text is no longer kept
P2I1A: no comparison — incorporated by reference
8-K Apr 23, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024 1: no comparison — no earlier filing on file
1A: no comparison — no earlier filing on file
7: no comparison — no earlier filing on file
8-K Feb 11, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 24, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Jul 24, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 8.01 Other events
8-K Apr 25, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.